Dataset from An Open-Label, Dose Escalation, Phase 1 Study of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007106
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary
purpose of this study is to determine the safety profile, establish the maximum tolerated
dose, and inform the phase 2 dose of IXAZOMIB administered intravenously in participants with
nonhematologic malignancies.
创建时间：
2025-10-01
